Yuhan Corporation (000105.KS)
KRW 101900.0
(-3.04%)
KRW 101900.0
(-3.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1858.98 Billion KRW | 4.68% |
| 2022 | 1775.84 Billion KRW | 5.22% |
| 2021 | 1687.81 Billion KRW | 4.19% |
| 2020 | 1619.86 Billion KRW | 9.42% |
| 2019 | 1480.35 Billion KRW | -2.53% |
| 2018 | 1518.82 Billion KRW | 3.87% |
| 2017 | 1462.24 Billion KRW | 10.71% |
| 2016 | 1320.79 Billion KRW | 17.02% |
| 2015 | 1128.73 Billion KRW | 10.93% |
| 2014 | 1017.49 Billion KRW | 7.83% |
| 2013 | 943.6 Billion KRW | 21.53% |
| 2012 | 776.45 Billion KRW | 14.31% |
| 2011 | 679.23 Billion KRW | 2.36% |
| 2010 | 663.57 Billion KRW | 2.6% |
| 2009 | 646.77 Billion KRW | 5.82% |
| 2008 | 611.18 Billion KRW | 23.9% |
| 2007 | 493.28 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 528.31 Billion KRW | 18.83% |
| 2024 Q1 | 444.59 Billion KRW | 1.7% |
| 2023 Q4 | 437.15 Billion KRW | -9.5% |
| 2023 FY | 1858.98 Billion KRW | 4.68% |
| 2023 Q1 | 443.04 Billion KRW | -1.65% |
| 2023 Q2 | 495.72 Billion KRW | 11.89% |
| 2023 Q3 | 483.06 Billion KRW | -2.55% |
| 2022 FY | 1775.84 Billion KRW | 5.22% |
| 2022 Q2 | 482.95 Billion KRW | 17.55% |
| 2022 Q1 | 410.85 Billion KRW | -3.09% |
| 2022 Q4 | 450.5 Billion KRW | 4.39% |
| 2022 Q3 | 431.53 Billion KRW | -10.65% |
| 2021 Q1 | 379.03 Billion KRW | -17.86% |
| 2021 Q2 | 433.33 Billion KRW | 14.33% |
| 2021 FY | 1687.81 Billion KRW | 4.19% |
| 2021 Q3 | 451.46 Billion KRW | 4.18% |
| 2021 Q4 | 423.97 Billion KRW | -6.09% |
| 2020 Q1 | 313.27 Billion KRW | -20.44% |
| 2020 Q3 | 429.68 Billion KRW | 3.42% |
| 2020 Q4 | 461.42 Billion KRW | 7.39% |
| 2020 FY | 1619.86 Billion KRW | 9.42% |
| 2020 Q2 | 415.48 Billion KRW | 32.63% |
| 2019 Q4 | 393.74 Billion KRW | 3.0% |
| 2019 Q2 | 359.39 Billion KRW | 4.19% |
| 2019 Q1 | 344.95 Billion KRW | -16.71% |
| 2019 FY | 1480.35 Billion KRW | -2.53% |
| 2019 Q3 | 382.25 Billion KRW | 6.36% |
| 2018 Q2 | 386.22 Billion KRW | 13.65% |
| 2018 FY | 1518.82 Billion KRW | 3.87% |
| 2018 Q4 | 414.17 Billion KRW | 9.39% |
| 2018 Q3 | 378.6 Billion KRW | -1.97% |
| 2018 Q1 | 339.82 Billion KRW | -9.92% |
| 2017 Q4 | 377.25 Billion KRW | -0.39% |
| 2017 FY | 1462.24 Billion KRW | 10.71% |
| 2017 Q1 | 351.19 Billion KRW | 0.41% |
| 2017 Q2 | 355.05 Billion KRW | 1.1% |
| 2017 Q3 | 378.73 Billion KRW | 6.67% |
| 2016 Q1 | 276.47 Billion KRW | -8.74% |
| 2016 Q2 | 332.74 Billion KRW | 20.35% |
| 2016 Q3 | 361.82 Billion KRW | 8.74% |
| 2016 FY | 1320.79 Billion KRW | 17.02% |
| 2016 Q4 | 349.75 Billion KRW | -3.33% |
| 2015 Q3 | 311.73 Billion KRW | 14.63% |
| 2015 Q4 | 302.97 Billion KRW | -2.81% |
| 2015 FY | 1128.73 Billion KRW | 10.93% |
| 2015 Q1 | 242.07 Billion KRW | -10.83% |
| 2015 Q2 | 271.94 Billion KRW | 12.34% |
| 2014 Q1 | 227.69 Billion KRW | -12.79% |
| 2014 FY | 1017.49 Billion KRW | 7.83% |
| 2014 Q4 | 271.46 Billion KRW | 3.92% |
| 2014 Q3 | 261.22 Billion KRW | 1.6% |
| 2014 Q2 | 257.1 Billion KRW | 12.92% |
| 2013 Q3 | 224.36 Billion KRW | -6.53% |
| 2013 Q4 | 261.08 Billion KRW | 16.37% |
| 2013 FY | 943.6 Billion KRW | 21.53% |
| 2013 Q1 | 218.11 Billion KRW | 10.45% |
| 2013 Q2 | 240.04 Billion KRW | 10.05% |
| 2012 Q2 | 205.02 Billion KRW | 23.1% |
| 2012 Q1 | 166.54 Billion KRW | 0.0% |
| 2012 Q3 | 203.85 Billion KRW | -0.57% |
| 2012 Q4 | 197.47 Billion KRW | -3.13% |
| 2012 FY | 776.45 Billion KRW | 14.31% |
| 2011 Q1 | 164.17 Billion KRW | 2.6% |
| 2011 FY | 679.23 Billion KRW | 2.36% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 164.65 Billion KRW | -3.66% |
| 2011 Q2 | 170.91 Billion KRW | 4.11% |
| 2010 Q3 | 157.79 Billion KRW | -5.96% |
| 2010 Q2 | 167.79 Billion KRW | 2.49% |
| 2010 Q1 | 163.72 Billion KRW | 5.26% |
| 2010 Q4 | 160.01 Billion KRW | 1.41% |
| 2010 FY | 663.57 Billion KRW | 2.6% |
| 2009 Q3 | 155.49 Billion KRW | -4.46% |
| 2009 Q4 | 155.54 Billion KRW | 0.03% |
| 2009 FY | 646.77 Billion KRW | 5.82% |
| 2009 Q1 | 156.55 Billion KRW | 0.43% |
| 2009 Q2 | 162.74 Billion KRW | 3.96% |
| 2008 Q4 | 155.88 Billion KRW | 2.87% |
| 2008 FY | 611.18 Billion KRW | 23.9% |
| 2008 Q1 | 137.25 Billion KRW | 13.44% |
| 2008 Q2 | 151.03 Billion KRW | 10.05% |
| 2008 Q3 | 151.54 Billion KRW | 0.33% |
| 2007 FY | 493.28 Billion KRW | 0.0% |
| 2007 Q1 | 105.65 Billion KRW | 0.0% |
| 2007 Q2 | 127.99 Billion KRW | 21.14% |
| 2007 Q3 | 127.56 Billion KRW | -0.33% |
| 2007 Q4 | 120.98 Billion KRW | -5.16% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -1254.85% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | -64.221% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -191.173% |
| HANDOK Inc. | 522.74 Billion KRW | -255.622% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -1273.234% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -179.976% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -3478.063% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | -24.69% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -1277.945% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -401.699% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -1998.328% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -996.31% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -728.214% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -1254.85% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -2281.687% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -1130.535% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -2027.869% |
| JW Holdings Corporation | 928.07 Billion KRW | -100.306% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -209.44% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | -11.356% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -148.352% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -828.431% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -928.411% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -846.791% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -155.92% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -1254.85% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | -22.749% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | -35.167% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -148.352% |
| Yuhan Corporation | 1858.98 Billion KRW | 0.0% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | -133.919% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -691.385% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -212.662% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -148.352% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -536.358% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -566.438% |
| CKD Bio Corp. | 160.35 Billion KRW | -1059.309% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -252.78% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -414.799% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -706.873% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -828.431% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | -111.301% |
| Boryung Corporation | 859.62 Billion KRW | -116.255% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -1376.225% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -401.699% |
| JW Lifescience Corporation | 206.86 Billion KRW | -798.666% |